SGRY | Ticker Profile - Titan Protect

SGRY

Surgery Partners, Inc.

Healthcare · Medical Care Facilities · NMS

$13.71

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.8B

Total market value of the company

Trailing P/E

N/A

Forward P/E

21.02

Based on estimated future earnings — lower means cheaper

Rev Growth

+4.5%

Year-over-year revenue change

Profit Margin

-2.3%

How much profit the company keeps from each dollar of revenue

ROE

2.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$17.50

+28% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 11 analysts covering this stock

About Surgery Partners, Inc.

Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care facilities; and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

https://www.surgerypartners.com

Country: United States Employees: 16,000 Industry: Medical Care Facilities

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

-0.441

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0491

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.436

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-28.7%

Historical annualised return based on price data

Max Drawdown

-65.9%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.99

Significantly more volatile than the market

52W High

$24.10

43% below the year high

52W Low

$11.41

20% above the year low

Avg Volume

1,585,309

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

22.0%

Very high short interest — potential squeeze candidate

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.59

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

116.01

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.86

Healthy liquidity position

Quick Ratio

1.35

Like current ratio but excludes inventory — stricter test

Gross Margin

22.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

10.4%

Profit from core operations before interest and tax

Free Cash Flow

$199M

Positive — the business generates more cash than it spends

Revenue (TTM)

$3.3B

Total revenue over the last 12 months

Net Income

$-76,100,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$24.00

Target Median

$17.50

Target Low

$14.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go